Successes from the sector

Biotech thrives through collaboration

Just like the Top Sector LSH itself, a biotech company cannot succeed without collaboration. Whether it be research programmes with academia, financial ties with investors, alignment with patient organisations or strategic collaboration with leading pharmaceutical companies, partnerships are the way to go. The road from lab to patient simply is too lengthy, too costly and too risky to travel alone.

Luckily, the Dutch LSH entrepreneurs prove to be more than capable to engage in innovative partnerships. And as a result, our biotech sector is growing and evolving steadily. Here, we list the tip of the iceberg: just a few of the many partnerships announced in 2016.

  • Merus announces closing of global strategic research collaboration with Incyte to discover and develop bispecific antibodies
  • Galapagos and AbbVie expand their cystic fibrosis collaboration
  • Genmab achieves USD 30 Million Milestone in Darzalex collaboration with Janssen, triggered by first commercial sale in Europe
  • Collaboration between Sanquin and Okklo enters new phase
  • Pluriomics in €2M alliance to develop in vitro heart failure models
  • Probiodrug and Crossbeta Biosciences enter into a strategic partnership in Alzheimer's disease
  • Synaffix Enters into a commercial license agreement with ADC Therapeutics
  • OcellO and Charles River Laboratories announce their strategic partnership to provide translational in vitro PDX and in vivo PDX oncology drug discovery services
  • Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates
  • GenDx signs reseller agreement with Illumina

Quote Annemiek Verkamman, HollandBIO: "The life sciences sector is a sector with a mission, full of passionate, ambitious and talented people. Cooperation is in the Dutch genes: our entrepreneurs travel the world to engage in innovative partnerships that will improve global health.”

LSH sector needs to consolidate strengths

Photography: Kick Smeets

Minister Edith Schippers: "It is amazing that so many parties are making an effort to improve healthcare. The medical world is developing at a rapid pace. There are a growing number of different and specific treatment possibilities. If patients get the most suitable treatment faster than that really makes a difference. And at the same time, it is vitally important that misdiagnoses or wrong treatments are prevented. This Health Deal can significantly contribute to that."

Chronic pain care
More than 2.2 million people suffer from chronic pain in the Netherlands, which has a significant impact on their daily lives and their environment. It leads to absence from work and occupational disability. Therefore this Health Deal is aimed at changing how pain patients are treated, by implementing improved standards of chronic pain care and providing more personalised care. In addition, it offers patients the right information by making use of eHealth applications to easily exchange knowledge between patient and healthcare provider.

In October, the second Health Deal on chronic pain care was signed by the Ministry of Health, Welfare and Sport, the Ministry of Economic Affairs, collaborative pain patient association, CIR, Vogellanden, Realhealth, Sint Maartenskliniek, Radboudumc, UMCG, Aratame Health, Diakonessenhuis, National Network Chronic Pain, VUmc, Zilveren Kruis, HINQ, and Happy Motion.

For further information, please contact the Netherlands Enterprise Agency.